Section of Hepatology, Department of Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Section of Hepatology, Department of Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Pharmacology and Therapeutics, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101694. doi: 10.1016/j.clinre.2021.101694. Epub 2021 Apr 10.
A low serum alkaline phosphatase (ALP) level is an uncommon finding in patients with chronic liver disease (CLD). The prevalence of this finding and whether low ALP expression influences CLD remain to be determined. The objectives of this study were: (1) to document the prevalence of low serum ALP levels in adult CLD patients and (2) compare features of CLD in patients with low versus normal or elevated serum ALP levels.
An adult, outpatient liver disease database was searched for patients with low serum ALP levels (<40 IU/L). Hepatic inflammation, function, fibrosis and disease severity were determined by serum aminotransferases, albumin, bilirubin and INR levels, Fib-4 calculations and MELD scores respectively.
Of 19,037 patients entered into the database, 47 (0.25%) had consistently low serum ALP levels, 51 (0.27%) low levels on the majority and 469 (2.44%) on the minority of determinations. Patients with consistently low levels were matched (1:2) by age, gender and nature of the underlying liver disease to patients with normal or elevated serum ALP levels. Matched patients with consistently low ALP levels had significantly lower serum aminotransferase and bilirubin levels at their initial visit and throughout the follow-up period (p < 0.05 respectively) while Fib-4 levels and MELD scores were similar at the initial and last follow-up visit.
These results establish the prevalence of low serum ALP levels in adult CLD patients and describe a hitherto unreported association between low serum ALP levels and less biochemical evidence of active disease.
血清碱性磷酸酶(ALP)水平低在慢性肝病(CLD)患者中较为少见。这种情况的患病率以及低 ALP 表达是否会影响 CLD 仍有待确定。本研究的目的是:(1)记录成年 CLD 患者低血清 ALP 水平的患病率;(2)比较低血清 ALP 水平与正常或升高的 CLD 患者的特征。
在成人门诊肝病数据库中搜索血清 ALP 水平较低(<40IU/L)的患者。通过血清转氨酶、白蛋白、胆红素和 INR 水平、Fib-4 计算和 MELD 评分分别确定肝炎症、功能、纤维化和疾病严重程度。
在纳入数据库的 19037 名患者中,47 名(0.25%)患者的血清 ALP 水平持续较低,51 名(0.27%)患者的大多数检测结果较低,469 名(2.44%)患者的少数检测结果较低。低水平持续的患者与正常或升高血清 ALP 水平的患者按年龄、性别和潜在肝病的性质进行匹配(1:2)。低 ALP 水平持续的匹配患者在首次就诊和随访期间的血清转氨酶和胆红素水平明显较低(分别为 p<0.05),而 Fib-4 水平和 MELD 评分在首次和最后一次随访时相似。
这些结果确定了成年 CLD 患者低血清 ALP 水平的患病率,并描述了低血清 ALP 水平与更活跃的疾病的生化证据之间以前未报道的关联。